ASTRAZEN6,843.00

AstraZeneca Pharma India Limited

· Pharma & Health
₹ CrorePeersSANOFICONRPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCMcap ₹17,108 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)644.70697.2539,512.6939,512.69
Receivable Days (DSO)43.1439.3234.2734.27
Payable Days (DPO)561.07580.0530,103.85
Cash Conversion Cycle (days)126.77156.529,443.11
Working Capital Turnover2.252.683.033.24
Asset Turnover1.201.131.141.14
Cash Conversion (CFO/Net Income)0.570.56-0.08-0.08
CFO/EBITDA0.500.26-0.06-0.06
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.